Loading...
Loading...
Merck
MRK, known as MSD outside the United States and Canada, announced
today that the U.S. Food and Drug Administration (FDA) approved JANUMET^ XR
(sitagliptin and metformin hydrochloride (HCl) extended-release) tablets, a
new treatment for type 2 diabetes that combines sitagliptin, which is the
active component of JANUVIA^ (sitagliptin), with extended-release metformin.
JANUMET XR provides a convenient once-daily treatment option for healthcare
providers and patients who need help to control their blood sugar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in